Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jul;28(1):160–162. doi: 10.1128/aac.28.1.160

Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.

E J Goldstein, D M Citron
PMCID: PMC176333  PMID: 3929677

Abstract

With a macrotube dilution method, MICs and MBCs were determined for three aminothiazolyl cephalosporins, cefpirome (HR 810), ceftazidime, and cefotaxime, against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-resistant, -susceptible, and -tolerant strains of Staphylococcus aureus. Comparatively, cefpirome was the most active agent against all gram-positive cocci, including enterococci and methicillin-resistant S. aureus, and was as active as ceftazidime against P. aeruginosa. MBCs of cefpirome were within two dilutions of the MICs for 91% of P. aeruginosa and 90% of gram-positive cocci strains tested, except methicillin-resistant S. aureus, for which the MBCs were within three dilutions for 90% of strains.

Full text

PDF
160

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertram M. A., Bruckner D. A., Young L. S. In vitro activity of HR 810, a new cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):277–279. doi: 10.1128/aac.26.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clumeck N., Gordts B., Dab I., Jaspar N., Van Laethem Y., Butzler J. P. Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):207–211. doi: 10.1093/jac/12.suppl_a.207. [DOI] [PubMed] [Google Scholar]
  3. Collins J. K., Mader J. T., Kelly M. T. Resistance of methicillin-resistant staphylococcus aureus to third-generation cephalosporins. J Infect Dis. 1983 Mar;147(3):591–591. doi: 10.1093/infdis/147.3.591. [DOI] [PubMed] [Google Scholar]
  4. File T. M., Jr, Tan J. S. Enterococcal sensitivity to third generation cephalosporins. Lancet. 1981 Aug 29;2(8244):477–477. doi: 10.1016/s0140-6736(81)90813-8. [DOI] [PubMed] [Google Scholar]
  5. Foord R. D. Ceftazidime: aspects of efficacy and tolerance. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):399–403. doi: 10.1093/jac/12.suppl_a.399. [DOI] [PubMed] [Google Scholar]
  6. Haley R. W., Hightower A. W., Khabbaz R. F., Thornsberry C., Martone W. J., Allen J. R., Hughes J. M. The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit. Ann Intern Med. 1982 Sep;97(3):297–308. doi: 10.7326/0003-4819-97-3-297. [DOI] [PubMed] [Google Scholar]
  7. Jones R. N., Thornsberry C., Barry A. L., Ayers L., Brown S., Daniel J., Fuchs P. C., Gavan T. L., Gerlach E. H., Matsen J. M. Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories. J Clin Microbiol. 1984 Sep;20(3):409–412. doi: 10.1128/jcm.20.3.409-412.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones R. N., Thornsberry C., Barry A. L. In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother. 1984 Jun;25(6):710–718. doi: 10.1128/aac.25.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones R. N., Thornsberry C. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S300–S315. doi: 10.1093/clinids/4.supplement_2.s300. [DOI] [PubMed] [Google Scholar]
  10. Kaye D. The clinical significance of tolerance of Staphylococcus aureus. Ann Intern Med. 1980 Dec;93(6):924–926. doi: 10.7326/0003-4819-93-6-924. [DOI] [PubMed] [Google Scholar]
  11. Klesel N., Limbert M., Schrinner E., Seeger K., Seibert G., Winkler I. Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals. Infection. 1984 Jul-Aug;12(4):286–292. doi: 10.1007/BF01645963. [DOI] [PubMed] [Google Scholar]
  12. Ramphal R., Kramer B. S., Rand K. H., Weiner R. S., Shands J. W., Jr Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):81–88. doi: 10.1093/jac/12.suppl_a.81. [DOI] [PubMed] [Google Scholar]
  13. Watanakunakorn C. Treatment of infections due to methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):376–378. doi: 10.7326/0003-4819-97-3-376. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES